Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

Court's summary

Amarin has failed to state a claim for actively inducing infringement of its brand-name drug’s patented uses in violation of 35 U. S. C. §271(b), so its complaint cannot withstand Hikma’s motion to dismiss.

From the syllabus prepared by the Reporter of Decisions. Not part of the Court's opinion.